Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : EARNINGS REPORTING - surprises, misses & more -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (581)	4/19/2001 6:54:57 AM
From: 2MAR$	Respond to of 762

IMNX ($16 unchanged) Q1 net income rises 24 pct SEATTLE, April 18 (Reuters) - Drug maker Immunex Corp. (NasdaqNM:IMNX - news) said Wednesday its first quarter profits rose 24 percent, just above Wall Street forecasts, as sales of its flagship anti-arthritis treatment Enbrel rose 26 percent. The Seattle-based company said net income for the quarter reached $39.8 million, or 7 cents a share, up from $32.2 million, or 6 cents a share, in the same period a year ago. Analysts polled by First Call/Thomson Financial had on average estimated quarterly profit at 6 cents a share, with projections ranging between 4 cents and 8 cents. Immunex said total revenues for the quarter rose to $217.8 million from $179.0 million in the first quarter of 2000. Enbrel sales rose to $164.9 million in the latest quarter, a gain of 26 percent over the same period in 2000.